19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Notch signaling pathway; hairy and enhancer of split1 (HES1)

Cancer INDICATION: Sarcoma In vitro and mouse studies suggest inhibiting Notch signaling could help treat dedifferentiated liposarcoma. In patient tissue samples, levels of the Notch pathway ligand HES1 were higher in tumors than in normal adipose tissue....
08:00 , Feb 4, 2010 |  BC Innovations  |  Cover Story

Revoking serotonin's auto license

Although the majority of marketed antidepressants are designed to boost low levels of the neurotransmitter serotonin in the brain-a well-known cause of depression-only a third of patients actually respond to the first drug they are...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Sep 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer ...